With a one year PEG ratio of 0.64, Castle Biosciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 5.92% of US stocks.
Castle Biosciences Inc's stock had its IPO on July 25, 2019, making it an older stock than just 1.6% of US equities in our set.
The price/operating cash flow metric for Castle Biosciences Inc is higher than 94.88% of stocks in our set with a positive cash flow.
Stocks that are quantitatively similar to CSTL, based on their financial statements, market capitalization, and price volatility, are AXTI, PING, MLAB, KRMD, and AYX.
Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.
Castle Biosciences ([[CSTL]] -5.7%) announced preliminary performance results for 4Q20 and FY20.Delivered 18,185 gene expression profile test reports in 2020.Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020. Since the effective date, more than 90% of Medicare beneficiaries whose clinicians order DecisionDx-Melanoma as part...